Mar 27 |
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
|
Mar 26 |
SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive
|
Mar 17 |
30 Biggest Biotechnology Companies in the World
|
Mar 14 |
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
|
Mar 12 |
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
|
Mar 10 |
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
|
Mar 10 |
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
|
Mar 7 |
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
|
Mar 4 |
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
|
Feb 29 |
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
|